CytomX Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- CytomX Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- Headquarters country
- United States
- Ticker symbol
- CTMX
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001501989
Board of directors
-
Alan Ashworth · DirectorSince 2023
-
Charles S. Fuchs · DirectorSince 2026
-
Elaine Jones V · DirectorSince 2023
-
Halley E. Gilbert · DirectorSince 2023
-
James R. Meyers · DirectorSince 2023
-
Mani Mohindru · DirectorSince 2023
-
Matthew P. Young · DirectorSince 2023
-
Sean A. McCarthy · Director · CEOSince 2023
-
Zhen Su · DirectorSince 2024
Chief executives
Sean A. McCarthy
· CEO
Dates unknown
Board connections
5 of this board's directors also sit on 7 other boards.
- via James R. Meyers
- via Halley E. Gilbert
- via Mani Mohindru
- via Zhen Su
- via Elaine Jones V
- via Halley E. Gilbert
- via James R. Meyers
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $1,693,718
- 6 sales by 4 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 3, 2026 | Carvajal Alejandra Officer (Chief Legal Officer) | Grant or award | +100,000 | — | — |
| Jun 15, 2026 | Ogden Christopher Officer (Chief Financial Officer) | Open-market sale | −1,624 | $3.05 | $4,953 |
| Mar 17, 2026 | Chu Yu-Waye Officer (Chief Medical Officer) | Open-market sale | −21,279 | $6.42 | $136,611 |
| Mar 17, 2026 | Sean A. McCarthy Director, Officer (CEO) | Open-market sale | −118,969 | $6.42 | $763,781 |
| Mar 17, 2026 | BELVIN MARCIA Officer (SVP, Chief Scientific Officer) | Open-market sale | −31,492 | $6.42 | $202,179 |
| Mar 17, 2026 | Ogden Christopher Officer (Chief Financial Officer) | Open-market sale | −19,323 | $6.42 | $124,054 |
| Feb 2, 2026 | Lester Rachael Officer (Chief Business Officer) | Grant or award | +20,000 | — | — |
| Feb 2, 2026 | Chu Yu-Waye Officer (Chief Medical Officer) | Grant or award | +75,000 | — | — |
| Feb 2, 2026 | BELVIN MARCIA Officer (SVP, Chief Scientific Officer) | Grant or award | +60,000 | — | — |
| Feb 2, 2026 | Ogden Christopher Officer (Chief Financial Officer) | Grant or award | +90,000 | — | — |
| Feb 2, 2026 | Sean A. McCarthy Director, Officer (CEO) | Grant or award | +210,000 | — | — |
| Nov 6, 2025 | Sean A. McCarthy Director, Officer (CEO) | Open-market sale | −101,793 | $4.54 | $462,140 |
| Jun 16, 2025 | BELVIN MARCIA Officer (SVP, Chief Scientific Officer) | Open-market sale | −13,884 | $2.69 | $37,348 |
| Jun 16, 2025 | Sean A. McCarthy Director, Officer (CEO) | Open-market sale | −55,511 | $2.69 | $149,325 |
| Jun 16, 2025 | Ogden Christopher Officer (Chief Financial Officer) | Open-market sale | −10,614 | $2.69 | $28,552 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.